RxDoctor Payments Data

Thomas Hinson, MD

Pulmonary Disease · Winston Salem, NCNPI 1538141767

Payments from drug & device makers

$10,699in general payments, 2019–2025

Across 611 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • Regeneron Healthcare Solutions, Inc.$508
  • United Therapeutics Corporation$500
  • Insmed, Inc.$447
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$10,55099%
  • Education$1501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,699 in reported general payments places this provider in the 75th percentile of 393 pulmonary disease providers in North Carolina.

See all pulmonary disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$143,438
Medicare patients
684
Services billed
2,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter721$566,716
OfevNintedanib Esylate33$428,698
Aralast NpAlpha-1-Proteinase Inhibitor13$319,023
Breztri AerosphereBudesonide/Glycopyr/Formoterol261$188,393
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$113,463
Breo ElliptaFluticasone/Vilanterol215$107,259
Spiriva RespimatTiotropium Bromide157$87,710
Stiolto RespimatTiotropium Br/Olodaterol Hcl137$83,819
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr147$72,394
Dupixent PenDupilumab14$55,435
Pirfenidone19$53,562
HizentraImmun Glob G(Igg)/Pro/Iga 0-5016$47,621
SymbicortBudesonide/Formoterol Fumarate123$40,948
Incruse ElliptaUmeclidinium Bromide49$16,659
XareltoRivaroxaban23$12,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,484$774,6771,178 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,406$600,227327 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,313$234,472398 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$307$113,46317 claims
CSL BehringHizentra$76$47,62116 claims
Johnson & JohnsonXarelto$13$12,72023 claims
PfizerEliquis$119$7,29412 claims
MerckDulera$303$3,36011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 393 pulmonary disease providers in North Carolina.

Other pulmonary disease in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →